Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blarcamesine in Early Alzheimer's Disease
NCT03790709Phase 3Completed
- Sponsor
- Anavex Life Sciences Corp.
- Start
- Jul 2018
- Primary completion
- Jun 2022
- Modality
- Classical Binding Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of blarcamesine in Alzheimer's disease (AD), sponsored by Anavex Life Sciences Corp.. Started Jul 2018; status: completed.
02
Drugs
blarcamesine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03790709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03790709.